N-(1H-Benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide

Catalog No. :
ACMFTK681
CAS No. :
107249-97-8
Molecular Formula :
C17H17N3O3
Molecular Weight :
311.34

IUPAC Name:N-(1H-benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide

N-(1H-Benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$110.00Login to see priceIn stockInquiry
250mg98%$187.00Login to see priceIn stockInquiry
1g98%$503.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(1H-Benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide
IUPAC NameN-(1H-benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide
Molecular FormulaC17H17N3O3
Molecular Weight311.34
SMILESCOC1=C(C=C(C=C1)CC(NC2=NC3=C(C=CC=C3)N2)=O)OC
InChI KeyBHDNCFNMLJKFHV-UHFFFAOYSA-N
SynonymBenzeneacetamide, N-1H-benzimidazol-2-yl-3,4-dimethoxy-;N-(1H-Benzo[d]imidazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide;WAY-656238
CAS No.107249-97-8
PubChem CID853078

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302
Precautionary Statement(s)
P264-P270-P301+P312-P330-P501

Synthetic Route by SureRoute

1. ACMFTK681 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAIGX892 route compound structure diagram
    ACAIGX89293-40-3 In Stock
  2. Plus
  3. ACXKWJ601 route compound structure diagram
    ACXKWJ601934-32-7 In Stock
  4. Then
  5. ACMFTK681 route product structure diagram
    ACMFTK681107249-97-8 In Stock
Inquiry

2. ACMFTK681 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVRJA542 route compound structure diagram
    ACVRJA54210313-60-7 In Stock
  2. Plus
  3. ACXKWJ601 route compound structure diagram
    ACXKWJ601934-32-7 In Stock
  4. Then
  5. ACMFTK681 route product structure diagram
    ACMFTK681107249-97-8 In Stock
Inquiry

Comments (0)